Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

[1]  T. Shimomura,et al.  MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel , 2010, Molecular Cancer Therapeutics.

[2]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[3]  R. Fucini,et al.  The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model , 2009, Molecular Cancer Therapeutics.

[4]  A. Chakravarty,et al.  The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents , 2009, Cell cycle.

[5]  S. Pinel,et al.  Les inhibiteurs des kinases Aurora , 2009 .

[6]  R. Cortese,et al.  Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells , 2008, Molecular Cancer Therapeutics.

[7]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[8]  I. Fidler,et al.  Murine models to evaluate novel and conventional therapeutic strategies for cancer. , 2007, The American journal of pathology.

[9]  Quentin Liu,et al.  Aurora A, mitotic entry, and spindle bipolarity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. López-Guillermo,et al.  Analysis of Aurora‐A and hMPS1 mitotic kinases in mantle cell lymphoma , 2006, International journal of cancer.

[11]  T. Grogan,et al.  Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures , 2005, Molecular Cancer Therapeutics.

[12]  C. Prigent,et al.  Aurora kinases, aneuploidy and cancer, a coincidence or a real link? , 2005, Trends in cell biology.

[13]  H. Saya,et al.  RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. , 2005, Cancer research.

[14]  KyungMann Kim,et al.  Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study , 2005, Cancer investigation.

[15]  Kaori Sasai,et al.  Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. , 2004, Cell motility and the cytoskeleton.

[16]  D. Niedzwiecki,et al.  Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma , 2004, Cancer.

[17]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[18]  Erich A Nigg,et al.  Aurora kinases link chromosome segregation and cell division to cancer susceptibility. , 2004, Current opinion in genetics & development.

[19]  Eiji Kohmura,et al.  Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells* , 2003, Journal of Biological Chemistry.

[20]  E. Nigg,et al.  Regulation of Aurora-A kinase on the mitotic spindle , 2003, Chromosoma.

[21]  W. Earnshaw,et al.  The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.

[22]  Richard Bayliss,et al.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. , 2003, Molecular cell.

[23]  H. Saya,et al.  Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells , 2003, Cell.

[24]  Y. Terada,et al.  Interaction of Aurora-A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells , 2003, The Journal of cell biology.

[25]  E. Nigg,et al.  Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. , 2003, Molecular biology of the cell.

[26]  S. Fujita,et al.  Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[27]  P. Lorigan,et al.  Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma , 2003, British Journal of Cancer.

[28]  J. Peters,et al.  The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint , 2003, The Journal of cell biology.

[29]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[30]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[31]  H. Saya,et al.  Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[32]  Yu-Li Wang,et al.  The Kinase Activity of Aurora B Is Required for Kinetochore-Microtubule Interactions during Mitosis , 2002, Current Biology.

[33]  Michael J. Lee,et al.  Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules , 2002, The Journal of cell biology.

[34]  C. Allis,et al.  Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases , 2002, Molecular and Cellular Biology.

[35]  Anthony A. Hyman,et al.  Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans , 2001, The Journal of cell biology.

[36]  C. Prigent,et al.  Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. , 1999, Journal of cell science.

[37]  A. Younes.  Paclitaxel-based treatment of lymphoma. , 1999, Seminars in oncology.

[38]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[39]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[40]  M. Dorée,et al.  The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly. , 1998, Journal of cell science.

[41]  R. Fisher,et al.  Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Glover,et al.  Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles , 1995, Cell.

[43]  L. North,et al.  Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. Wilson,et al.  Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Astier,et al.  [Inhibitors of aurora kinases]. , 2009, Annales pharmaceutiques francaises.

[46]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[47]  N. Keen,et al.  Progress in the development of selective inhibitors of Aurora kinases. , 2005, Current topics in medicinal chemistry.

[48]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[49]  D. Bearss,et al.  Structure-based design of novel anti-cancer agents targeting aurora kinases. , 2003, Current medicinal chemistry. Anti-cancer agents.

[50]  E. Nigg.  Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.

[51]  J. Blay,et al.  Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. , 2000, Haematologica.

[52]  A. Stamatoullas,et al.  Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin ' s lymphomas , 2000 .

[53]  J. Bartek,et al.  Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.